Strengthening the team
PharmNovo has strengthened the team with a new experienced Project Manager and a Clinical trial manager to continue the development of the company's drug candidate PN6047 for the treatment of neuropathic pain, so-called nerve pain.
Inge Tarnow joins the team as the new Senior project manager and will lead and coordinate the work with PN6047. Inge Tarnow holds a Ph.D. in pathophysiology and is a Doctor of Veterinary Medicine. She has worked as a project manager at Savara, a biopharmaceutical company focusing on rare respiratory diseases, for six years.
PharmNovo also welcomes Thomas Eskildsen, Senior Clinical Trial Manager. He will oversee the phase I study while being an asset to the team in the planning and managing future phase IIa studies.
Strengthening the team
PharmNovo has strengthened the team with a new experienced Project Manager and a Clinical trial manager to continue the development of the company's drug candidate PN6047 for the treatment of neuropathic pain, so-called nerve pain.
Inge Tarnow joins the team as the new Senior project manager and will lead and coordinate the work with PN6047. Inge Tarnow holds a Ph.D. in pathophysiology and is a Doctor of Veterinary Medicine. She has worked as a project manager at Savara, a biopharmaceutical company focusing on rare respiratory diseases, for six years.
PharmNovo also welcomes Thomas Eskildsen, Senior Clinical Trial Manager. He will oversee the phase I study while being an asset to the team in the planning and managing future phase IIa studies.
Latest news
View all
Phase I study completed for PN6047
In August 2022, PharmNovo initiated the First-In-Human, (FIH), clinical study for the company’s drug candidate PN6047, aimed at evaluating its safety and tolerability. By August 2023, the study was completed, involving 104 subjects across 13 cohorts, which included both Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) cohorts. Each cohort consisted of 8 subjects, with 6 receiving active treatment and 2 receiving placebo.
Read more
PharmNovo presented at the BioStock Investor Meeting
PharmNovo participated at the BioStock Investor Meeting in Stockholm on September 20. Our CEO presented the development and phase I clinical study of our drug candidate PN6047, which is in its final phase.
Read more
No abuse potential shown in preclinical studies
We are delighted to share promising preclinical results for our innovative drug candidate PN6047, further confirming its safety profile. PN6047 is designed to provide relief from neuropathic pain, and these findings reinforce our commitment to safe and effective pain management as we prepare for Phase II trials in 2024.
Read more